Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis

Blood

Volumn 98, Issue 5, 2001, Pages 1532-1541

  Van Der Kuip, Heiko ^a,b,c   Goetz, Alexander W ^a,b,c   Miething, Cornelius ^a,b,c   Duyster, Justus ^a,b,c   Aulitzky, Walter E ^a,b,c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CELL PROTEIN; CYTOCHROME C; FIBRONECTIN; GROWTH FACTOR; INTEGRIN; LAMININ; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; POLYLYSINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DAMAGE; CELL FUNCTION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSKELETON; CYTOSOL; DNA DAMAGE; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; GAMMA IRRADIATION; GENE OVEREXPRESSION; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 0035469895     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1532     Document Type: Article

References (83)

1. Wang JY. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev. 1993;3:35-43.
2. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988;85:9312-9316.
3. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1987;84:6558-6562.
4. Lugo TG, Witte ON. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol. 1989;9:1263-1270.
5. Sawyers CL. The bcr-abl gene in chronic myelogenous leukaemia. Cancer Surv. 1992;15:37-51.
6. Tauchi T, Broxmeyer HE. BCR/ABL signal transduction. Int J Hematol. 1995;61:105-112
7. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;181:307-313.
8. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 1990;247:824-830.
9. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
10. Harlharan IK, Harris AW, Crawford M, et al. A bcrv-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol. 1989;9:2798-2805.
11. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemialike syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
12. Oetzel C, Jonuleit T, Götz A, et al. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by downregulating BCL-X, Clin Cancer Res. 2000;6:1958-1968.
13. Bedi A, Barber JP, Bedi GC, et al. BCR/ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148-1158.
14. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83:2038-2044.
15. Laneuville P, Timm M, Hudson AT. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res. 1994;54:1360-1366.
16. Sanchez-Garcia I, Martin-Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol. 1997;267:225-228.
17. Jonuleit T, van der Kuip H, Miething C, et al. Bcr/Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood. 2000;96:1933-1939.
18. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333-2342.
19. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996;98:521-528.
20. Salgia R, Li JL, Ewaniuk DS, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997;100:46-57.
21. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
22. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
23. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
24. Jonuleit, T, Peschel C, Schwab R, et al. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol. 1998;100:295-303.
25. Matsuguchi T, Salgia R, Hallek M, et al. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994;269:5016-5021.
26. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541.
27. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
28. Skorski T, Nieborowska-Skorska M, Szczylik C, et al. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res. 1995;55:2275-2278.
29. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910.
30. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR/ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254.
31. Gotoh A, Miyazawa K, Ohyashiki K, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol. 1995;23:1153-1159.
32. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995;11:1149-1155.
33. Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem. 1997;272:33260-33270.
34. Bai RY, Jahn T, Schrem S, et al. The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Oncogene. 1998;17:941-948.
35. Coutinho S, Jahn T, Lewitzky M, et al. Characterization of Ggrb4, an adapter protein interacting with Bcr-Abl. Blood. 2000;96:618-624.
36. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746-11750.
37. Pull L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773.
38. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183:811-820.
39. Kumar CC. Signaling by integrin receptors. Oncogene. 1998;17:1365-1373.
40. O'Neill GM, Fashena SJ, Golemis EA. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol. 2000;10:111-119.
41. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol. 1995;11:549-599.
42. Ginsberg MH, Du X, Plow EF, Inside-out integrin signalling. Curr Opin Cell Biol. 1992;4:766-771.
43. Kolanus W, Zeitlmann L. Regulation of integrin function by inside-out signaling mechanisms. Curr Top Miorobiol Immunol. 1998;231:33-49.
44. Shibayama H, Anzai N, Ritchie A, Zhang S, Mantel C, Broxmeyer HE. Interleukin-3 and Fit3-ligand induce adhesion of Baf3/FIt3 precursor B-lymphoid cells to fibronectin via activation of VLA-4 and VLA-5. Cell Immunol. 1998;187:27-33.
45. Shibayama H, Anzai N, Braun SE, Fukuda S, Mantel, Broxmeyer HE. H-Ras is involved in the inside-out signaling pathway of interleukin-3-induced integrin activation. Blood. 1999;93:1540-1548.
46. Levesque JP, Leavesley DI, Niutta S, Vadas M, Simmons PJ. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med. 1995;181:1805-1815.
47. Salgia R, Sattler M, Pisick E, L JL, Griffin JD. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996;24:310-313.
48. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood. 1994;84:2912-2918.
49. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest. 1992;90:1232-1241.
50. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood. 1996;97:3883-3891.
51. Hurley RW, McCarthy JB, Verfaillie CM. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest. 1995;96:611-619.
52. Skourides PA, Perera SA, Ren R. Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins. Oncogene. 1999;18:1165-1176.
53. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92:3780-3792.
54. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96:4319-4327.
55. Sanchez-Garcia, Grütz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A. 1995;92:5287-5291.
56. Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna JL. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood. 1996;87:3837-3843.
57. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
58. Kim CN, Wang X, Huang Y, et al. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 1997;57:3115-3120.
59. Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191:977-984.
60. Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91:1700-1705.
61. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285:1028-1032.
62. Datta K, Bellacosa A, Chan TO, Tsichlis PN. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem. 1996;271:30835-30839.
63. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol. 1999;19:5800-5810.
64. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
65. Neshat MS, RaitanoAB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20:1179-1186.
66. Boudreau NJ, Jones PL. Extracellular matrix and integrin signalling: the shape of things to come. Biochem J. 1999;339:481-488.
67. Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998;8:437-441.
68. Plantefaber LC, Hynes RO. Changes in integrin receptors on oncogenically transformed cells. Cell. 1989;56:281-290.
69. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res. 1999;76:1-20.
70. Verfaillie CM, Hurley R, Zhao RC, et al. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J Lab Clin Med. 1997;129:584-591.
71. Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol. 1997;97(1-2):40-52.
72. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 1993;12:1533-1546.
73. Wetzler M, Talpaz M, Van Etten RA, et al. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest. 1993;92:1925-1939.
74. Bhatia R, Munthe H, Verfaillie CM. Role of abnormal integrin-cytoskeletal interactions in impaired bl integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol. 1999;27:1384-1396.
75. + cell proliferation: BCR/ABL upregulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc Natl Acad Sci U S A. 2000;97:10538-10543.
76. Jiang Y, Prosper F, Verfaillie CM. Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors. Blood. 2000;95:846-854.
77. Guinebault C, Payrastre B, Racaud-Sultan C, et al. Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Biol. 1995;129:831-842.
78. Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1994;91:10148-10152.
79. Cary LA, Guan JL. Focal adhesion kinase in integrin-mediated signaling. Front Biosci. 1999;4: D102-D113.
80. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275:661-665.
81. Papayannopoulou T, Craddock C. Homing and trafficking of hemopoietic progenitor cells. Acta Haematol. 1997;97:97-104.
82. Fischer T, Neubauer A, Mohm J, et al. Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML. Bone Marrow Transplant. 1998;21:1029-1036.
83. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120:646-652.